Jubilant Pharmova
BSE 530019
7 stories, newest first.
- India Ratings assigns IND AA+/Stable to Jubilant Pharmova's proposed NCDs of Rs. 1,400.00 crore
- ICRA assigns [ICRA]AA+ (Stable) to Jubilant Pharmova's proposed Rs. 1,400.00 crore non-convertible debentures
- Board approves up to 80,000 NCDs of ₹1,00,000 each, aggregating up to ₹800 crore, on private placement basis
- Board approves NCD issue of up to ₹800 crore, seeks members' nod for ₹2,500 crore debt securities
- Radiopharma business to invest CAD 94.5 million to double RUBY-FILL production capacity
- Board meeting on October 12, 2026 to consider fund raising via NCDs and shareholder approval
- Specimen letter to physical shareholders on dividend withheld for FY 2025-26 pending KYC
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.